Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689600 | 0.82 | HDAC1 (0.51) | HDAC1HDAC6NOTUM | |
| Trifluoroacetic Acid SCHEMBL1689684 | 0.81 | HDAC1 (0.42) | HDAC1HDAC6NOTUMCYP2D6 | |
| SCHEMBL10253494 | 0.80 | NOTUM (0.44) | HDAC1HDAC6NOTUMCYP2D6 | |
| SCHEMBL1689945 | 0.75 | HDAC1 (0.49) | HDAC1HDAC6 | |
| SCHEMBL1689938 | 0.75 | HDAC1 (0.49) | HDAC1HDAC6 | |
| SCHEMBL10253695 | 0.74 | HDAC1 (0.45) | HDAC1HDAC6 | |
| SCHEMBL2351817 | 0.73 | HDAC1 (0.40) | HDAC1HDAC6 | |
| SCHEMBL2347648 | 0.72 | NOTUM (0.46) | HDAC1HDAC6NOTUMPROKR1 | |
| SCHEMBL4151601 | 0.71 | HDAC1 (0.43) | HDAC1HDAC6PROKR1CYP2D6 | |
| SCHEMBL4151596 | 0.71 | HDAC1 (0.43) | HDAC1HDAC6PROKR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515969-B2 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2017-10-11 | — | — | EP | disclosed |
| EP-1880996-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2012-01-12 | — | — | US | disclosed |
| EP-1515969-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-1880996-A1 | Spiroindolinepiperidine derivatives | Syngenta Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010220-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | HDAC1 620/4885HDAC6 117/4885NOTUM 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.